Skip to main content
Close
Publicación

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Ver todas las publicaciones
Not available in
This is not available in . You can go to the translated versions in these languages: